Therefore, before using CGRP monoclonal antibody in migraine patients, it is necessary to evaluate whether there is a potential factor for cerebral ischemia; for patients with increased risk of stroke, CGRP McAb should be used cautiously. The gene discussed is CALCA; the disease is brain ischemia.